Wednesday, July 29

Browsing: CyclinDependent

Support

106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice

By NewsCancerMay 18, 20260

BackgroundCDK4/6 inhibitors (CDK4/6i) plus endocrine therapy are the first-line standard of care for hormone receptor–positive/HER2-negative (HER2–negative) metastatic breast cancer. A…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Browsing: CyclinDependent

106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

SETD8-mediated mono-methylation of YAP at K76 promotes K48-linked polyubiquitination and degradation to suppress colorectal cancer

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

SETD8-mediated mono-methylation of YAP at K76 promotes K48-linked polyubiquitination and degradation to suppress colorectal cancer

Latest Post

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Subscribe to Updates

What's Hot

Browsing: CyclinDependent